Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Post by Dachs1on Feb 22, 2016 3:30am
204 Views
Post# 24580678

Bausch + Lomb / Obagi / India

Bausch + Lomb / Obagi / IndiaBausch + Lomb launches Obagis blockbuster products in India for transformational skincare // Bausch + Lomb has forayed into Indias skincare segment, with the launch of Obagis blockbuster products like Thermage, Fraxel, Vaser & Clear + Brilliant and few more offerings in the pipeline. The division has been registering growth in double digits. This strategic move of expanding in the premium skincare segment, would further strengthen Bausch + Lombs position in the INR 285 - 290 billion beauty care market, growing at a rate 15 to 20 per cent per annum (As per FICCI Wellness Report 2013). Bausch + Lomb intends to cater to the demands of niche Indian consumers, who constantly seek premium skincare solutions with high efficacy and visible results. The product portfolio includes a wide range of formulations designed to address skin concerns like premature skin aging, skin damage, hyperpigmentation, acne and sun damage. In India, within the beauty and skincare segment, the anti-aging category holds tremendous growth potential. As per our estimates, the anti-ageing market is growing by 30-50 per cent year-on-year which is much higher than the category growth. The primary drivers are increased consumer awareness, beauty consciousness and knowledge, as well as the aspiration to look young, said Sanjay Bhutani, managing director, India & SAARC at Bausch + Lomb India. Obagi is the number one physician recommended skincare brand in US with an annual sales of around $95 million. (Source: Professional Skin care: US market analysis & opportunities. March 2014 Kline report). In the first phase of its entry in the skincare segment, Bausch + Lomb has launched Hydrate Moisturizer, Professional-C Serums and ELASTIderm, from the targeted solutions and essential products portfolio for home care. It has also launched Obagi Blue peel which is into the professional care range. Over the next couple of years, our focus would be to consistently expand Obagis presence in India through introduction of new products, and achieve a market share of 5 per cent in the next 3 years, in the premium skincare segment, added Sanjay Bhutani, managing director India & SAARC, Bausch + Lomb. In addition to the skincare products, Bausch + Lomb also plans to launch Obagis highly-targeted skincare procedures, during the next phase of expansion. The products will be available through Indias leading physicians, primarily dermatologists, plastic surgeons, and other skin care and medical professionals. // https://pharmabiz.com/ArticleDetails.aspx?aid=90459&sid=13
Bullboard Posts